Translational studies of new treatments for movement disorders, including phase II and phase IIII clinical studies.
DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.
Neuropharmacology. 2017 Nov 29;:
Mov Disord. 2017 Nov 13;:
Conf Proc IEEE Eng Med Biol Soc. 2017 Jul;2017:3377-3380
Semin Neurol. 2017 Apr;37(2):147-157
ACS Chem Neurosci. 2017 May 01;:
A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma.
Br J Haematol. 2017 Apr 25;:
Mov Disord. 2017 Mar 30;:
Curr Neurol Neurosci Rep. 2017 Jan;17(1):3
Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.
JAMA Neurol. 2016 Dec 12;:
Cutis. 2016 Oct;98(4):E10-E12